Open AccessSaxagliptin for patients with T2D and renal impairment
Publication year - 2011
Publication title -
future prescriber
Language(s) - English
Resource type - Journals
eISSN - 1931-2261
pISSN - 1468-9871
DOI - 10.1002/fps.74
Subject(s) - saxagliptin , medicine , tolerability , type 2 diabetes , placebo , diabetes mellitus , intensive care medicine , alternative medicine , endocrinology , adverse effect , sitagliptin , pathology
Saxagliptin (Onglyza) now offers a further treatment option for patients with type 2 diabetes and moderate to severe renal impairment, improving glycaemic control compared with placebo with a favourable tolerability profile.